Halozyme's lead drug fails; company will cut 55% of workforce

Halozyme's lead drug fails; company will cut 55% of workforce

STAT Plus: Halozyme’s lead drug fails; company will cut 55% of workforce in bid for profitability

By MATTHEW HERPER

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

The company will refocus on its drug delivery technology, which is being used by drug giants including Roche, Johnson & Johnson, and Bristol-Myers Squibb.

READ MORE